Akero Therapeutics, Inc clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   Efruxifermin · Compensated Cirrhosis Due to NASH/MASH

   Start date pushed from Sep 4, 2024 to Oct 4, 2024

   Also in this update: Trial sites expanded: 331 → 345 locations

   Akero Therapeutics, Inc·Phase 3· NCT06528314· Registry history of NCT06528314 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.